Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Heart Warning Added to Pfizer’s ‘Z-Pak’ Antibiotic by FDA

March 12 (Bloomberg) -- Doctors should be aware of potential risks to patients with heart conditions when prescribing the antibiotic azithromycin, U.S. regulators said.

The Food and Drug Administration today updated the labeling information on the drug to reflect increased risk of fatal irregular heartbeats in patients. Research published last year found that the pills, used to treat infections, caused a small increase in cardiovascular deaths, especially among people with a higher risk of heart problems.

“Health-care professionals should consider the risk of fatal heart rhythms with azithromycin when considering treatment options for patients who are already at risk,” the FDA said in a statement today on the label change. The agency said azithromycin isn’t alone in carrying heart risks.

Zithromax is made by Pfizer Inc., the world’s largest drugmaker, and multiple generic manufacturers, and sometimes goes by the names Zithromax, Zmax or Z-Pak. The medicine generated about $435 million for New York-based Pfizer in 2012. It’s prescribed to treat bacterial infections of the respiratory system and urinary tract and for tonsillitis.

Pfizer has updated the label on the drug, said Lauren Starr, a company spokeswoman.

“The majority of patients treated with Zithromax (azithromycin) are not affected by this label update,” Starr said in an e-mail. The drug “has had a well established benefit risk profile for more than 20 years and continues to be an effective treatment option for patients all over the globe suffering from many types of bacterial infections.”

Pfizer fell 1.1 percent to $27.94 at the close in New York.

To contact the reporter on this story: Drew Armstrong in New York at darmstrong17@bloomberg.net;

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.